LLY Straddle Strategy
LLY (Eli Lilly and Company), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
LLY (Eli Lilly and Company) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $956.74B, a trailing P/E of 35.95, a beta of 0.48 versus the broader market, a 52-week range of 623.78-1133.95, average daily share volume of 3.1M, a public-listing history dating back to 1972, approximately 47K full-time employees. These structural characteristics shape how LLY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.48 indicates LLY has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 35.95 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. LLY pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a straddle on LLY?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current LLY snapshot
As of May 14, 2026, spot at $1,007.39, ATM IV 33.76%, IV rank 35.97%, expected move 9.68%. The straddle on LLY below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this straddle structure on LLY specifically: LLY IV at 33.76% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 9.68% (roughly $97.50 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LLY expiries trade a higher absolute premium for lower per-day decay. Position sizing on LLY should anchor to the underlying notional of $1,007.39 per share and to the trader's directional view on LLY stock.
LLY straddle setup
The LLY straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LLY near $1,007.39, the first option leg uses a $1,005.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LLY chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LLY shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1,005.00 | $36.10 |
| Buy 1 | Put | $1,005.00 | $36.50 |
LLY straddle risk and reward
- Net Premium / Debit
- -$7,260.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$6,993.28
- Breakeven(s)
- $932.40, $1,077.60
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
LLY straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on LLY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$93,239.00 |
| $222.75 | -77.9% | +$70,965.16 |
| $445.49 | -55.8% | +$48,691.32 |
| $668.23 | -33.7% | +$26,417.48 |
| $890.96 | -11.6% | +$4,143.64 |
| $1,113.70 | +10.6% | +$3,610.20 |
| $1,336.44 | +32.7% | +$25,884.04 |
| $1,559.18 | +54.8% | +$48,157.87 |
| $1,781.92 | +76.9% | +$70,431.71 |
| $2,004.66 | +99.0% | +$92,705.55 |
When traders use straddle on LLY
Straddles on LLY are pure-volatility plays that profit from large moves in either direction; traders typically buy LLY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
LLY thesis for this straddle
The market-implied 1-standard-deviation range for LLY extends from approximately $909.89 on the downside to $1,104.89 on the upside. A LLY long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current LLY IV rank near 35.97% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on LLY should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LLY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LLY-specific events.
LLY straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LLY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LLY alongside the broader basket even when LLY-specific fundamentals are unchanged. Always rebuild the position from current LLY chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on LLY?
- A straddle on LLY is the straddle strategy applied to LLY (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With LLY stock trading near $1,007.39, the strikes shown on this page are snapped to the nearest listed LLY chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LLY straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the LLY straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 33.76%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$6,993.28 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LLY straddle?
- The breakeven for the LLY straddle priced on this page is roughly $932.40 and $1,077.60 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LLY market-implied 1-standard-deviation expected move is approximately 9.68%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on LLY?
- Straddles on LLY are pure-volatility plays that profit from large moves in either direction; traders typically buy LLY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current LLY implied volatility affect this straddle?
- LLY ATM IV is at 33.76% with IV rank near 35.97%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.